DMD Simcyp

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Court, M. H.
Right arrow Articles by Greenblatt, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Court, M. H.
Right arrow Articles by Greenblatt, D. J.

Vol. 27, Issue 11, 1293-1299, November 1999

Propofol Hydroxylation by Dog Liver Microsomes: Assay Development and Dog Breed Differences

Michael H. Court, Bonnie L. Hay-Kraus, Dennis W. Hill, Albert J. Kind, and David J. Greenblatt

Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine, Boston, Massachusetts (M.H.C., D.J.G.); Department of Clinical Sciences, Tufts University School of Veterinary Medicine, North Grafton, Massachusetts (M.H.C., B.L.H-K.); and Microchemistry Laboratory, Pathobiology Department, University of Connecticut, Storrs, Connecticut (D.W.H., A.J.K.)

Pharmacokinetic studies indicate that clearance of propofol, an anesthetic agent, is slower in greyhounds compared with other dog breeds. Biotransformation of propofol to 2,6-diisopropyl-1,4-quinol (4-hydroxypropofol) by cytochrome P-450 in the liver is proposed as a critical initial step in the elimination of this drug in dogs. Breed differences in the activity of this enzyme could therefore explain pharmacokinetic differences. An in vitro propofol hydroxylase assay was developed and then used to compare enzyme activities in liver microsomes from male greyhound, beagle, and mixed-breed dogs (five each). HPLC of incubate identified only one NADPH-dependent metabolite, which had a chromatographic retention time and UV absorbance, fluorescence, and mass spectra that were identical with authentic 4-hydroxypropofol standard. HPLC with fluorescence detection provided a highly sensitive quantitation method for 4-hydroxypropofol with a quantitation limit of 8 ng/ml using optimized excitation/emission wavelengths (288 nm/330 nm, respectively). Estimates of apparent Km and Vmax for propofol hydroxylation by microsomes from a male beagle dog were 7.3 µM and 3.8 nmol/mg/min, respectively. At a substrate concentration of 20 µM, propofol hydroxylase activity was significantly lower (p = .032) in greyhound microsomes (1.7 ± 0.4 nmol/mg/min) compared with beagle microsomes (5.1 ± 1.3 nmol/mg/min) but was not statistically different (p = .42) compared with mixed-breed microsomes (3.1 ± 1.2 nmol/mg/min). These results indicate that there are breed differences in propofol hydroxylase activity and that deficient hydroxylation of propofol by one or more hepatic cytochrome P-450 isoforms may contribute to slow pharmacokinetic clearance of propofol by greyhounds.


Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Toxicol PatholHome page
J. Tibbitts
Issues Related to the Use of Canines in Toxicologic Pathology--Issues With Pharmacokinetics and Metabolism
Toxicol Pathol, January 1, 2003; 31(1_suppl): 17 - 24.
[Abstract] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1999 by the American Society for Pharmacology and Experimental Therapeutics.